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Abstract  
The psychotomimetic effect of the N-methyl-D-aspartate receptor (NMDAR) 
antagonist ketamine is thought to arise from a functional modulation of the brain’s 
fronto-striato-thalamic (FST) circuits. Animal models suggest a pronounced effect on 
ventral “limbic” FST systems, though recent work in patients with psychosis and 
high-risk individuals suggests specific alterations of dorsal “associative” FST circuits. 
Here, we used functional magnetic resonance imaging to investigate the effects of a 
sub-anaesthetic dose of ketamine on measures of functional connectivity as indexed 
by the temporal coherence of spontaneous neural activity in both dorsal and ventral 
FST circuits, as well as their symptom correlates. We adopted a placebo-controlled, 
double-blind, randomized, repeated-measures design in which 19 healthy participants 
received either an intravenous saline infusion or a racemic mixture of ketamine 
(100ng/ml) separated by at least 1 week. Compared to placebo, ketamine increased 
functional connectivity between the dorsal caudate and both the thalamus and 
midbrain bilaterally. Ketamine additionally increased functional connectivity of the 
ventral striatum/nucleus accumbens and ventromedial prefrontal cortex. Both 
connectivity increases significantly correlated with the psychosis-like and dissociative 
symptoms under ketamine. Importantly, dorsal caudate connectivity with the 
ventrolateral thalamus and subthalamic nucleus showed inverse correlation with 
ketamine-induced symptomatology pointing to a possible resilience role to 
disturbances in FST circuits. While consistent with the role of FST in mediating 
psychosis, these findings contrast with previous research in clinical samples by 
suggesting that acute NMDAR antagonism may lead to psychosis-like experiences via 
a mechanism that is distinct from that implicated in frank psychotic illness. 
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Introduction: 
NMDAR hypofunction is thought to play a primary role in the pathophysiology of 
psychosis (Javitt and Zukin, 1991; Olney and Farber, 1995). Its effects are commonly 
modeled in healthy volunteers by administration of ketamine, a potent antagonist of 
NMDARs on cortical GABAergic cells which leads to disinhibited glutamatergic 
stimulation of non-NMDA (i.e. kainate and AMPA) receptors (Moghaddam et al, 
1997; Olney et al, 1995). These effects have a downstream impact on mesocortical 
and mesolimbic dopamine pathways (Adams and Moghaddam, 1998; Moghaddam et 
al, 1997). In addition, ketamine infusion increases blood flow and metabolic activity 
in the prefrontal cortex, striatum and thalamus (Holcomb et al, 2001; Vollenweider et 
al, 1997), effects which strongly correlate with the emergence of dissociative and 
psychosis-like symptoms (Driesen et al, 2013; Holcomb et al, 2001; Vollenweider et 
al, 1997). Disruption of fronto-striato-thalamic (FST) circuitry is thought to play a 
major role in the pathogenesis of schizophrenia and dissociative phenomena (Pantelis 
et al, 1992).  
FST circuits comprise a set of parallel yet integrated loops serving distinct and 
complementary functions (Alexander et al, 1986). This functional specificity raises 
the question of whether ketamine exerts its psychiatric effects through selective 
modulation of activity in one circuit over another. Animal models suggest that 
NMDAR inhibition leads to schizophrenia-like behaviour and increased dopamine in 
the ventral, so-called “limbic” FST circuit, linking the medial prefrontal cortex and 
the ventral/limbic striatum (i.e., nucleus accumbens) (Moghaddam et al, 1997). In 
contrast, recent human molecular imaging studies have found that both patients with 
psychotic disorders and those with an “at-risk mental state” (ARMS) for psychosis 
show increased dopamine transmission in the dorsal, so-called “associative” striatum 
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(Howes et al, 2009; Kegeles et al, 2010), and that these changes correlate with 
symptom severity and abnormal dorsal prefrontal cortical activation (Fusar-Poli et al, 
2011). Such findings suggest that the psychotomimetic effects of ketamine may arise, 
in part, from its influence on dopamine transmission in dorsal FST circuits. 
Alternatively, ketamine might induce psychosis-like experiences through an 
independent mechanism, given evidence that dopamine D2 receptor blockade does 
not attenuate ketamine-induced psychotic symptoms (Krystal et al, 1999; Lahti et al, 
1995). 
In light of these possibilities, we sought to characterize the effects of a sub-
anaesthetic dose of ketamine on the temporal coherence—i.e., functional 
connectivity—of spontaneous neural activity of dorsal and ventral FST circuits as 
measured using resting-state functional magnetic resonance imaging (fMRI) in 
healthy young adults. Resting-state fMRI offers a powerful means to map the 
functional integrity of large-scale brain networks and their modulation with 
pharmacological agents (Cole et al, 2012; Driesen et al, 2013). Our own recent work 
has identified a prominent reduction of functional connectivity in dorsal FST circuits 
in ARMS subjects, first-episode schizophrenia patients, and their unaffected first-
degree relatives (Dandash et al, 2013; Fornito et al, 2013). As such, if the 
psychotomimetic effects of ketamine arise through a mechanism similar to that seen 
in patients with psychosis and ARMS individuals, ketamine should act primarily by 
reducing functional connectivity in dorsal FST circuitry. A distinct mode of action 
would be suggested by alternative FST functional connectivity changes. 
 
Materials and Methods  
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Participants 
Twenty-one participants (10 males; mean age 28.7 years, SD = 3.2 years); were 
recruited via advertisements placed throughout central Cambridge, UK. All 
participants were right-handed; free of current of previous psychiatric or neurological 
disorder or substance abuse problems; and had no history of cardiovascular illness or 
family history of psychiatric disorder/substance abuse. All participants provided 
written informed consent in accordance with ethics committee guidelines. 
 
Study Design  
 
Participants were assessed on two occasions, separated by at least one week. On one 
occasion, they received a continuous computer-controlled intravenous infusion of a 
racemic ketamine solution (2mg/ml) until a targeted plasma concentration of 100 
ng/ml was reached. This concentration was sustained throughout the protocol. A 
saline infusion was administered on the other occasion. Infusion order was randomly 
counterbalanced across participants. The infusion was performed and monitored by a 
trained anaesthetist (RA) who was unblinded for safety reasons, but who otherwise 
had minimal contact with participants. At all other times, participants were supervised 
by investigators blinded to the infusion protocol (AF and RG). The participants 
remained blinded until both assessments were completed. All MRI and assessment 
procedures were identical across assessment occasions. 
 
Infusion Protocol 
Bilateral intravenous catheters were inserted into volunteers’ forearms, one for 
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infusion, and the other for serial blood sampling. The infusions were administered 
using a computerized pump (Graseby 3500, Graseby Medical Ltd. UK) programmed 
to target a constant plasma concentration of 100ng/ml, using the pharmacokinetic 
parameters of a three-compartment model (Domino et al, 1982). The infusion 
continued for 15 minutes to allow stabilization of plasma levels. Blood samples were 
drawn prior to and after the resting fMRI scan and then placed on ice. Plasma was 
obtained by centrifugation and stored at -70oC. Plasma ketamine concentrations were 
measured by gas chromatography-mass spectrometry.  
 
Clinical measures 
 
Once the infusion had stabilized and prior to MRI, participants underwent a clinical 
rating of positive psychotic symptoms as assessed by the Rating Scale for Psychotic 
Symptoms (RSPS) (Chouinard and Miller, 1999) and the Brief Psychiatric Rating 
Scale (BPRS) (Overall and Gorham, 1962). Seven key items on the BPRS 
representing positive symptoms of the psychosis prodrome (somatic concerns, 
anxiety-depression, elevated mood, grandiosity, hallucination, and unusual thought 
content) were selected. Dissociative symptoms were assessed by the Clinician 
Administered Dissociative States Scale (CADSS) (Bremner et al, 1998). In addition, 
participants completed assessments of psychosis-proneness (Chapman magical 
ideation (Eckblad and Chapman, 1983) and perceptual aberration scales (Chapman et 
al, 1978) and the Peters delusion inventory (Peters et al, 1999)) prior to the first scan.  
 
MRI acquisition  
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Scanning was performed using a 3.0 T MRI scanner (Siemens Magnetom, Trio Tim, 
Erlangen, Germany) equipped with a 12-channel array coil located at the Wolfson 
Brain Imaging Centre, Addenbrooke’s Hospital, Cambridge, UK. T2*-weighted echo-
planar images were acquired under eyes-closed resting-state conditions. Participants 
were instructed to close their eyes and let the minds wander without going to sleep. 
Subsequent participant debriefing ensured that no participants fell asleep during the 
scan. Imaging parameters were: 3x3x3.75mm voxel size, with a time-to-repetition 
(TR) of 2000ms, time-to-echo (TE) of 30ms, flip angle of 78° in 64 x 64 matrix size 
and 240mm field of view (FOV). 300 volumes comprising 32 slices each were 
obtained. In addition, high-resolution anatomical T1 images were acquired using a 3-
dimensional magnetic-prepared rapid gradient echo (MPPRAGE) sequence. 176 
contiguous sagittal slices of 1.0 mm thickness using a TR of 2300ms, TE of 2.98ms, 
flip angle of 9°, and a FOV of 256mm, in 240 x 256 matrix were acquired with a 
voxel size of 1.0 mm3.  
 
Preprocessing  
An established procedure was used to characterize corticostriatal functional 
connectivity in relation to six seed regions located in ventral and dorsal areas of the 
caudate nucleus and putamen per hemisphere (Dandash et al, 2013; Di Martino et al, 
2008; Fornito et al, 2013). Seeds were defined in both hemispheres as 3.5 mm radial 
spheres at the following stereotaxic coordinates: dorsal caudate (x = ±13, y = 15, z = 
9); ventral striatum/nucleus accumbens (x = ±9, y = 9, z = -8); dorsal-caudal putamen 
(x = ±28, y = 1, z = 3) ventral-rostral putamen (x = ±20, y = 12, z = -3). Image 
preprocessing was performed using statistical parametric mapping software (SPM8) 
and included motion correction and coregistration of functional images with subjects’ 
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anatomical scans, which were concurrently normalized to SPM-T1 template. The 
resulting transformation matrix was applied to the functional data to achieve accurate 
spatial normalization across individuals. The anatomical scans were also segmented 
using a unified normalization and segmentation approach . Segmented white matter 
and CSF images were thresholded at 50% tissue probability and binarized to create 
nuisance variable masks, together with a binary mask of the global brain volume 
(summed from the gray matter, white matter, and CSF segments). Although it has 
been suggested that the removal of the global signal can possibly induce negative or 
anti-correlated relationships between brain regions (Murphy et al, 2009), a large body 
of competing evidence suggests that the removal of the global signal significantly 
improves the specificity of resting-state fMRI results (see (Van Dijk et al, 2010) for a 
detailed analysis and an extensive list of supporting evidence). In addition, it is highly 
unlikely that the between-condition comparisons are confounded by this 
preprocessing step given that the removal of the global signal was identically 
performed across both conditions, ketamine and placebo.  
 
Functional images were smoothed using a Gaussian filter (full-width at half-
maximum, 8 mm). All image sequences were routinely inspected for potential 
normalization artifacts. Mean time series were then extracted from each seed region 
and each nuisance mask for each participant. Two participants were excluded for 
excessive head motion ( >2 mm translation and >2° rotation), resulting in a final 
sample of 19 subjects. 
 
First-level, within-subjects analysis. 
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For each participant, functional connectivity maps were estimated using whole-brain 
general linear models as implemented in SPM8. Prior to model estimation, each of the 
three nuisance covariates (white matter, cerebrospinal fluid and global mean signals) 
and six head motion parameters (three translation, three rotation) were orthogonalized 
with respect to each seed’s time series, resulting in a model comprising six ‘noise-
cleaned’ regions and 9 nuisance variables. Data were high-pass filtered (~0.008 Hz 
cutoff) and contrast images were generated for each participant by estimating the 
regression coefficient between all brain voxels and each region’s time-series 
separately for left and right hemisphere seeds. 
  
Second-level, between-condition analysis 
For each striatal region, participant-specific contrast images were included in a 
random-effects 2 x 2 factorial design [Condition (placebo, ketamine) by Hemisphere 
(left, right)]. Within-condition statistical maps were thresholded at a false discovery 
rate (FDR) of P<.05 for the whole brain volume (Figure 1). Between-condition effects 
(main effects of condition and condition x hemisphere interactions) were mapped by 
implicitly masking the t-contrasts (1-tailed) with a global conjunction of the within-
subjects striatal seed main effect across ketamine and placebo for the combined left 
and right hemispheres. Nuisance covariates included four additional summary 
measures of head motion unaccounted for by the first-level correction procedure (Van 
Dijk et al, 2012). Between-condition statistical maps were thresholded using a P<.05 
family-wise error (FWE) cluster-wise corrected threshold determined by a 
permutation-test based on the AlphaSim  algorithm (1000 permutations with a cluster-
forming threshold of P<.01 uncorrected), as implemented in the REST toolbox (Song 
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et al, 2011). 
 
Brain-behaviour analysis 
 
The difference between symptom scores obtained under placebo and ketamine 
(ketamine-placebo) was computed to obtain change scores for each scale, denoted by 
ΔBPRS, ΔRSPS, and ΔCADSS. (One outlier was excluded from BPRS analysis.) 
These change scores were correlated, on a voxel-wise basis, with subject-specific 
parameter estimates for the effect of ketamine (vs placebo) on striatal functional 
connectivity, masked by regions showing a significant ketamine effect on functional 
connectivity (Figure 2). The four aforementioned summary measures of head motion 
were included as nuisance variables in these analyses. All results were displayed at a 
FWE cluster-wise corrected level of P<.05, with appropriate correction for the search 
volume employed. Secondary analyses tested for associations between functional 
connectivity changes and trait-like measures of psychosis proneness (i.e., the 
Chapman and Peters scales).  
 
Results 
Plasma concentrations and symptom ratings 
The mean plasma concentration of ketamine before and after scanning was 
68.6±43.6ng/ml. Ketamine caused a significant increase in psychosis-like and 
dissociative symptoms as indexed by the RSPS, BPRS and the CADSS, respectively 
(Table 1). Endorsed RSPS items pertained mainly to somatosensory perturbations and 
loss of attention focus; BPRS items included grandiosity, elevated mood, anxiety, 
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delusional thoughts, and hallucinations; and CADSS items pertained to external and 
reality perception. These symptoms concur with previous reports (Krystal et al, 1994). 
Ketamine-induced symptomatology was not accompanied by changes in head motion 
as found by a formal between-condition comparison.  
 
Functional connectivity analyses 
Collapsed across placebo and ketamine conditions, the four seed-specific striatal 
functional connectivity maps closely recapitulated previous studies (Figure 1; (Di 
Martino et al, 2008; Harrison et al, 2009)). Compared to placebo, ketamine 
augmented functional connectivity of the dorsal caudate and ventral striatum/nucleus 
accumbens seeds only. Specifically, functional connectivity was increased between 
the dorsal caudate and regions in the thalamus and midbrain bilaterally (Figure 2A), 
and increased between the ventral striatum and left anterior and ventromedial 
prefrontal cortex (Figure 2B). There were no significant effects of ketamine on 
putamen functional connectivity; no significant condition-by-hemisphere interactions; 
and no significant functional connectivity decreases observed under ketamine relative 
to placebo.  
 
Brain-behavior associations 
A stronger ketamine-related increase of functional connectivity between the dorsal 
caudate and right midbrain was correlated with higher ΔRSPS scores (Figure 3A). 
Conversely, a stronger effect of ketamine on functional connectivity between dorsal 
caudate and left ventrolateral thalamus, as well as between dorsal caudate and 
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subthalamic nucleus, was associated with lower ΔRSPS and lower ΔCADSS scores 
(Figure 3B). In the ventral system, higher ketamine-induced functional connectivity 
between ventral striatum and left ventromedial prefrontal cortex was associated with 
higher ΔBPRS scores (Figure 3C), while higher ΔCADSS scores were associated with 
a stronger ketamine effect on functional connectivity between the ventral striatum and 
an adjacent ventromedial prefrontal region (Figure 3D). All results were FWE cluster-
wise corrected (P<.05) for multiple comparisons. No significant associations were 
observed between measures of psychosis-proneness (i.e. the Chapman and Peters 
scales) and ketamine-induced functional connectivity changes.  
  
Discussion 
Ketamine increased functional connectivity between specific components of both 
dorsal and ventral fronto-striato-thalamic (FST) circuits and these increases correlated 
with the emergence of psychosis-like and dissociative phenomena assessed with the 
BPRS, RSPS and the CADSS, respectively. These drug induced functional 
connectivity changes contrast with the alterations found in patients with first-episode 
psychosis, their unaffected relatives and ARMS individuals (Dandash et al, 2013; 
Fornito et al, 2013) who show reduced functional connectivity in dorsal FST systems 
and less consistent evidence for ventral circuit alterations (Dandash et al, 2013; 
Fornito et al, 2013). Specifically, two primary differences were noted. First, ketamine 
led to a general increase, rather than decrease, in both dorsal and ventral circuit 
functional connectivity. Second, the dorsal circuit increases were primarily 
subcortical, affecting functional coupling of the dorsal caudate with midbrain and 
thalamus (Figure 2A), rather than the frontostriatal changes seen in clinical 
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populations. These findings imply that the psychosis-like experiences elicited by an 
acute dose of ketamine arise from FST alterations that are distinct from those 
associated with the primary pathophysiological disturbance in psychosis.   
 
The general increase in FST functional connectivity is consistent with past reports 
that ketamine augments regional resting cerebral blood flow, metabolic and 
electrophysiological activity, and resting-state functional connectivity in these and 
other regions (Driesen et al, 2013; Holcomb et al, 2001; Vollenweider et al, 1997). 
This effect is thought to arise from excitation-inhibition imbalance (Anticevic et al, 
2012) caused by ketamine’s blockade of NMDARs on inhibitory GABAergic 
interneurons that leads to the disinhibition of glutamate release, resulting in excess 
glutamatergic binding at AMPA and kainate receptors (Moghaddam et al, 1997). The 
striatum receives afferent glutamatergic input from the prefrontal cortex and sends 
efferents to the thalamus via the pallidum and midbrain. The thalamus projects back 
to the originating prefrontal area completing a fronto-striato-thalamic loop (Alexander 
et al, 1986). Influential models of psychosis posit that increased flow of sensory 
information from the striatum to the thalamus results in a failure of the thalamus to 
“filter-out” irrelevant stimuli before they reach the cortex, thus predisposing 
individuals to psychotic symptoms (Carlsson, 1988). The associations we found 
between the emergence of psychosis-like symptoms and ketamine-induced increases 
of functional connectivity (Figure 3) support this view, under the assumption that 
increased functional connectivity reflects increased AMPA/kainate-mediated feed-
forward fronto-striatal and striato-thalamic signaling. However, this result is at odds 
with the lack of subcortical functional connectivity increases observed in first episode 
patients and ARMS individuals (Dandash et al, 2013; Fornito et al, 2013).  
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Dysregulation of dopamine likely plays a central role in the risk-related FST changes 
observed in clinical samples, given robust evidence for elevated dopaminergic 
function, particularly in dorsal striatal regions, in both patients (Kegeles et al, 2010) 
and high-risk individuals (Howes et al, 2009). Either too much or too little dopamine 
in FST circuits is expected to reduce neural signal-to-noise ratio (Cools and 
D'Esposito, 2011) and thus lower functional connectivity (Fornito et al, 2013). 
NMDAR hypofunction has been implicated as a candidate upstream cause of the 
dopaminergic abnormalities associated with psychosis onset (Carlsson and Carlsson, 
1990) and some human studies suggest that ketamine augments dopamine release in a 
manner that parallels observations in clinical sample (Kegeles et al, 2000), while also 
impacting the activation of frontostriatal systems (Corlett et al, 2006). However, other 
studies have failed to demonstrate that ketamine increases striatal dopamine 
transmission, even with very high doses (Aalto et al, 2002); that ketamine has a 
limited effect on D2 receptor availability (Kegeles et al, 2002); and that treatment 
with Haloperidol has no impact on ketamine-induced psychotic symptoms (Krystal et 
al, 1999; Lahti et al, 1995). These findings suggest a mode of action for ketamine that 
diverges from the pathophysiological alterations seen in psychosis patients.  
 
Though our findings support a distinct mode of action for ketamine, two 
considerations merit discussion. The first pertains to dosage. Participants in our study 
received a lower dose of ketamine than is traditionally used (Aalto et al, 2002; 
Kegeles et al, 2002; Krystal et al, 1994) to maximize in-scanner tolerance. Though 
the dose was sufficient to elicit an increase in psychosis-like and dissociative 
symptoms, their intensity and quality may have been more characteristic of an ARMS 
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than frank psychotic episode. Nonetheless, dorsal FST functional connectivity 
reductions have still been observed in ARMS individuals (Dandash et al, 2013) and 
symptom-free genetic high-risk volunteers (Fornito et al, 2013), suggesting such 
changes are present at the earliest signs of illness. Moreover, functional connectivity 
reductions are by far the most common finding in patients with psychosis across 
different illness stages and neural systems (Pettersson-Yeo et al, 2011), contrasting 
the generic functional connectivity increases observed in this study and elsewhere, 
even when using much higher doses (~162 ng ml-1)(Driesen et al, 2013). These results, 
combined with other evidence that the dose we used is sufficient to effectively model 
other psychosis-related brain changes in healthy volunteers (Corlett et al, 2006), 
support the conclusion that not all of the neural effects of ketamine adequately model 
the brain changes seen in clinical samples, even when they correlate with drug-
induced increases in symptomatology (Pomarol-Clotet et al, 2006). Thus, ketamine 
may provide a better model of some risk-related brain changes than others. 
 
 
A second consideration regards to the chronicity of exposure. It has been argued that 
acute NMDAR hypofunction may model neural changes associated with cognitive 
disturbances that pre-date psychosis onset (e.g., akin to an ARMS) (Corlett et al, 
2007), whereas longer-term deficits may be more characteristic of schizophrenia 
(Freeman et al, 2009). In this regard, early hyperconnectivity of FST circuits may 
evolve into subsequent hypoconnectivity as psychosis takes hold. This view is 
supported by reports that striatal glutamate is elevated in early stages of schizophrenia  
but reduces with antipsychotic treatment (de la Fuente-Sandoval et al, 2013); that 
administration of ketamine is associated with reduced functional connectivity in some 
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brain circuits after 24 hours (Scheidegger et al, 2012); and that chronic but not acute 
use of ketamine leads to delusion formation (Freeman et al, 2009) that persists after 
abstinence (Morgan et al, 2010). However, the fact that dorsal FST hypoconnectivity 
is observed in ARMS individuals (Dandash et al, 2013) and symptom-free first-
degree relatives of patients populations (Fornito et al, 2013) which putatively 
represent the earliest illness stages, suggests that acute ketamine infusion provides an 
inadequate model of risk-related FST dysconnectivity. Whether chronic exposure 
better models these changes is an open question. 
 
Interestingly, while ketamine-related increases of functional connectivity were 
generally associated with more severe psychosis-like and dissociative symptoms, 
increased connectivity between dorsal caudate and regions of the thalamus and sub-
thalamic nucleus was associated with lower symptom scores (Figure 3B). Others have 
found that ketamine-induced negative symptoms inversely correlate with functional 
connectivity changes of the ventrolateral thalamus with the rest of the brain (Driesen 
et al, 2013). The thalamus and subthalamic nucleus are thought to exert modulatory 
feedback over striatal output within cortico-striato-thalamic circuits (Parent and 
Hazrati, 1995). While the modulatory role of the ventrolateral thalamus on dorsal 
striatum is less clear , glutamatergic cells in the thalamus and sub-thalamic nucleus 
(STN) are proposed to initiate a cascade of events resulting in activation of 
GABAergic cells in the pallidum, thus dampening outflow from the striatum 
(Carlsson, 1988; Carlsson et al, 1990). This feedback is believed to prevent overflow 
of sensory information, and its failure has been implicated in vulnerability to 
psychotic experiences (Carlsson et al, 1990). Accordingly, our findings indicate that 
individuals who engaged this system to a greater extent experienced fewer psychosis-
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like and dissociative symptoms under ketamine. Up-regulating functional connectivity 
in this circuit may represent a viable treatment target to combat the deleterious effects 
of dysfunction elsewhere in the system. 
 
Whilst we have focused on the known influence of ketamine on ionotropic glutamate 
receptors and dopaminergic signaling, the drug can impact on other modulatory 
systems (Kapur and Seeman, 2002). However, the average dose used herein provides 
less than 0.1 μM available for binding (assuming plasma binding value of 47% 
(Dayton et al, 1983) and a molecular weight of 274.19 (ketamine hydrochloride)). At 
this concentration ketamine demonstrates no binding potential for most other 
receptors (e.g. mu opioid, sigma, dopamine or 5-HT)(Kapur et al, 2002; Smith et al, 
1987).  
 
In summary, our findings suggest that ketamine impacts functional connectivity of 
both dorsal and ventral FST circuits and that these changes correlate with the severity 
of psychosis-like and dissociative symptoms induced by the drug. They also point to a 
potential role for the ventrolateral thalamus and subthalamic nucleus in protecting 
against disturbances that lead to psychotic experience. While consistent with the role 
of FST in mediating psychosis, these effects appear somewhat distinct from the FST 
changes observed in first episode patients, unaffected relatives and ARMS individuals, 
suggesting that acute ketamine infusion does not completely model the disturbances 
of FST functional connectivity implicated in risk for psychosis. Investigating the 
impact of NMDAR agonists as well as glutamate antagonists on the functional 
connectivity of the ventrolateral thalamus and subthalamic nucleus is important to 
further delineate their protective role. 
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Figure legends 
 
Figure 1: Significant within-group functional connectivity maps of the dorsal caudate 
(DC), ventral striatum/nucleus accumbens (VS), dorsal putamen (DP) and ventral 
putamen (VP) seeds (in blue). Green indicates connectivity under placebo; red 
indicates connectivity under ketamine infusion; yellow indicates areas of overlap. R, 
right hemisphere; L, left hemisphere. Sagittal slices are displayed at x = ±6. Results 
are displayed at P<.05 (FDR corrected). 
Figure-2: Z-score statistical maps of significant between-condition differences in 
functional connectivity of the (A) dorsal caudate (DC) and (B) ventral striatum (VS). 
R, right hemisphere; L, left hemisphere. Coordinates correspond to MNI space. 
Results are displayed at P<.05 (FWE cluster-wise corrected).  
Figure-3: Z-scores statistical maps of significant brain-behavior association between 
estimates of functional connectivity of striatal seeds and positive psychotic and 
dissociative symptoms caused by ketamine infusion, displayed at P<.05 (FWE 
cluster-wise corrected). For visualizing purposes parameter estimates were extracted 
from peak voxels in the shown brain maps and correlated with symptom change 
scores. 
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Table 1: Symptom scores of healthy participants before and after the administration 
of ketamine. 
Psychotic and dissociative symptoms 
measures (n = 19) Placebo  mean (SD)
Ketamine 
mean (SD) 
Wilcoxon 
signed-ranks  
Z, P 
Brief Psychotic Rating Scale (BPRS) 7.7 (2.3) 9.7 (3.7) -2.53, P=.011 
Rating Scale for Psychotic Symptoms 
(RSPS) 2.3 (4.3) 20.2 (16.8) -3.55, P<.001 
Clinician Administered Dissociative 
States Scale (CADSS) 0.5 (1.2) 18.2 (16.7) -3.73, P<.001 
Psychosis-proneness measures (n=16)1 Baseline 
mean (SD)
_ _ 
Chapman Magical Ideation scale 3.5 (3.6) _ _ 
Chapman Perceptual Aberration scale 4.1 (6.7) _ _ 
Peters Delusion Inventory 36.8 (31.1) _ _ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
1 Values for 3 subjects were not available 
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Table2: Brain regions demonstrating significant between-condition (ketamine greater 
than placebo) differences in functional connectivity and association with symptom 
change scores (ketamine – placebo). Results are thresholded at P<.05 (FWE) cluster-
wise corrected. DC: Dorsal Caudate; VS: Ventral Striatum. 
 
Main Effect 
(Figure 2) 
Anatomical Region Hemisphere 
MNI Peak 
Coordinates 
x,y,z 
Z 
(df=1,68) 
Voxels 
(A) DC 
Thalamus Right 6,-18,2 3.64 
552 
Thalamus Left -14,-18,6 3.38 
Midbrain Left -18,-16,-12 3.38 
Midbrain Right 12,-16,-10 2.88 
(B) VS 
Superior 
ventromedial 
prefrontal cortex 
Left -8,64,2 3.62 
582 
Frontopolar Cortex Left -6,68,-6 3.22 
Inferior 
ventromedial 
prefrontal cortex 
Left -16,62,-2 3.06 
Behavioral 
Association 
(Figure 3) 
Anatomical Region Hemisphere 
MNI Peak 
Coordinates 
x,y,z 
Z 
(df=1,31) 
Voxels 
(A) DC 
(RSPS) 
Midbrain Right 8, -12, -10 2.65 12 
(B) DC 
(CADSS) 
Ventrolateral 
thalamus & sub-
thalamic nucleus 
Left -18,-12,0 2.86 18 
(B) DC 
(RSPS) 
Ventrolateral 
thalamus & sub-
thalamic nucleus 
Left -12,-14,2 3.11 31 
(C) VS 
(BPRS) 
Superior 
ventromedial 
prefrontal cortex 
Left -16,64,4 3.722 145 
                                                        
2 (df=1,29) An outlier was excluded from the analysis (see Brain-behaviour 
analysis in the Methods section for more information) 
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(D) VS 
(CADSS) 
Inferior 
ventromedial 
prefrontal cortex 
Left -6,60,-10 4.04 47 
 



